Cost-effectiveness of antihypertensive treatment: metoprolol versus thiazide diuretics.
The aim of the present analysis was to calculate the cost-effectiveness of metoprolol versus thiazide diuretics in middle-aged men with mild to moderate uncomplicated hypertension.  The analysis was based on the Metoprolol Atherosclerosis Prevention in Hypertensives (MAPHY) study, a randomised trial which showed a significantly lower risk for coronary events in patients taking metoprolol than in patients on thiazide diuretics.  The main analysis was based on Swedish costs, but the costs were also varied in a special sensitivity analysis.  Metoprolol was shown to be cost-saving compared with thiazide diuretics when both direct and indirect costs of morbidity were included.  When only direct costs were included, the cost per life-year gained was $US2400.  The result of the present analysis suggests that metoprolol is to be preferred to thiazide diuretics from a cost-effectiveness standpoint in the treatment of mild to moderate hypertension in middle-aged men.  These findings regarding cost-effectiveness should, however, not be extrapolated to patient groups not included in the MAPHY trial.
Centre for Health Economics, Stockholm School of Economics, Sweden.
M
M
Johannesson
J
J
Wikstrand
B
B
Jönsson
G
G
Berglund
J
J
Tuomilehto
D001581:Benzothiadiazines; D003362:Cost-Benefit Analysis; D004232:Diuretics; D006801:Humans; D006973:Hypertension / Q000188:drug therapy*; D008017:Life Expectancy; D008297:Male; D008790:Metoprolol / Q000191:economics* / Q000627:therapeutic use; D008875:Middle Aged; D012307:Risk Factors; D049993:Sodium Chloride Symporter Inhibitors / Q000191:economics* / Q000627:therapeutic use; D016896:Treatment Outcome